Language selection

Search

Archived — COVID-19 Therapeutics Task Force Registry of Interests

Note:

This is an archived page. The mandate of the COVID-19 Therapeutics Task Force ended on February 28, 2021.

Arch Biopartners
Name of Member Nature of Interest Action Taken
Cédric Bisson None N/A
Nancy Harrison None N/A
Maha Katabi None N/A
Gordon McCauley None N/A
Parimal Nathwani None N/A
Ali Tehrani Did not attend meeting N/A
Youla Tsantrizos None N/A
Lisa Barrett None N/A
Marceline Côté None N/A
Eleanor Fish None N/A
Matthias Götte Did not attend meeting N/A
François Jean None N/A
Samira Mubareka None N/A
Pamela Ohashi None N/A
James Russell None N/A
Makeda Semret None N/A
Don Sheppard None N/A
Don Vinh None N/A

 

Edesa
Name of Member Nature of Interest Action Taken

Cédric Bisson

Identified a financial interest

Recused himself from deliberations and recommendations

Nancy Harrison

None

N/A

Maha Katabi

None

N/A

Gordon McCauley

None

N/A

Parimal Nathwani

None

N/A

Ali Tehrani

Noted that he knows some of the applicants personally, but has no interest with the proposal

Not considered a conflict and recusal not deemed necessary

Youla Tsantrizos

None

N/A

Lisa Barrett

None

N/A

Marceline Côté

None

N/A

Eleanor Fish

None

N/A

Matthias Götte

None

N/A

François Jean

None

N/A

Samira Mubareka

None

N/A

Pamela Ohashi

Did not attend meeting

N/A

James Russell

Did not attend meeting

N/A

Makeda Semret

None

N/A

Don Sheppard

None

N/A

Don Vinh

None

N/A

Benjamin Rovinski(Vaccine Task Force observer)

Identified a financial interest

Recused himself from deliberations and recommendations

 

Eli Lilly / AbCellera
Name of Member Nature of Interest Action Taken
Cédric Bisson Noted an indirect financial and business interest with Eli Lilly, unrelated to COVID-19 Recused himself from deliberations and recommendations
Nancy Harrison Noted business interaction with AbCellera, unrelated to COVID-19 Recused herself from deliberations and recommendations
Maha Katabi Noted a potential financial and business interest Recused herself from deliberations and recommendations
Gordon McCauley Noted business interaction with AbCellera, unrelated to COVID-19 Recused himself from deliberations and recommendations
Parimal Nathwani None N/A
Ali Tehrani Noted an indirect financial and business interest with Eli Lilly, unrelated to COVID-19 Recused himself from deliberations and recommendations
Youla Tsantrizos None N/A
Lisa Barrett Noted a scientific interest, as Principal Investigator on a study that includes a different Eli Lilly COVID-19 product Recused herself from deliberations and recommendations
Marceline Côté None N/A
Eleanor Fish None N/A
Matthias Götte None N/A
François Jean None N/A
Samira Mubareka None N/A
Pamela Ohashi None N/A
James Russell Identified historical interactions with Eli Lilly, but no current relationship Not considered a conflict and recusal not deemed necessary
Makeda Semret None N/A
Don Sheppard None N/A
Don Vinh None N/A

 

Remdesivir
Name of Member Nature of Interest Action Taken
Cédric Bisson None N/A
Nancy Harrison None N/A
Maha Katabi None N/A
Gordon McCauley None N/A
Parimal Nathwani None N/A
Ali Tehrani None N/A
Youla Tsantrizos None N/A
Lisa Barrett Noted an indirect scientific interest, working on a trial that includes remdesivir Not considered a conflict and recusal not deemed necessary
Marceline Côté None N/A
Eleanor Fish None N/A
Matthias Götte Identified a direct scientific and financial interest, related to work on remdesivir and relationship with Gilead Sciences Recused himself from deliberations and recommendations
François Jean None N/A
Samira Mubareka None N/A
Pamela Ohashi None N/A
James Russell None N/A
Makeda Semret Noted an indirect scientific interest, working on a trial that will include remdesivir Not considered a conflict and recusal not deemed necessary
Don Sheppard None N/A
Don Vinh None N/A
Date modified: